Aytu Biopharma (AYTU) Revenue Growth (5y) (2019 - 2025)
Powered by 
Analysis
Aytu Biopharma (AYTU) Revenue Growth (5y) (2019 - 2025) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 643.26 Bn | 622.50 Bn | 17.26 Bn |
| 2 | AbbVie | 443.31 Bn | 436.74 Bn | 12.70 Bn |
| 3 | Merck | 364.74 Bn | 357.60 Bn | 12.21 Bn |
| 4 | Novartis Ag | 266.46 Bn | 258.77 Bn | 11.24 Bn |
| 5 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn |
| 6 | Sanofi | 52.33 Bn | 44.95 Bn | 10.79 Bn |
| 7 | Revolution Medicines | 43.79 Bn | 43.79 Bn | - |
| 8 | Incyte | 25.23 Bn | 20.69 Bn | 1.57 Bn |
| 9 | United Therapeutics | 21.67 Bn | 19.01 Bn | 683.80 Mn |
| 10 | Aytu Biopharma | 22.49 Mn | -4.22 Mn | 7.60 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | 0.02% |
| Sep 30, 2025 | 0.54% |
| Jun 30, 2025 | 0.37% |
| Mar 31, 2025 | 17.74% |
| Dec 31, 2024 | 38.57% |
| Sep 30, 2024 | 63.01% |
| Jun 30, 2024 | 53.44% |
| Mar 31, 2024 | 42.61% |
| Dec 31, 2023 | 59.87% |
| Sep 30, 2023 | 65.57% |
| Jun 30, 2023 | 101.50% |
| Mar 31, 2023 | 106.36% |
| Dec 31, 2022 | 90.37% |
| Sep 30, 2022 | 91.41% |
| Jun 30, 2022 | 101.04% |
| Mar 31, 2022 | 93.44% |
| Dec 31, 2021 | 96.26% |
| Sep 30, 2021 | 99.21% |
| Jun 30, 2021 | 90.45% |
| Dec 31, 2020 | 100.35% |